Propanc Biopharma Inc. has received a notice from the Nasdaq Stock Market indicating non-compliance with the $1.00 minimum bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2). While this notice does not result in immediate delisting, the company faces the risk of its stock being removed from the Nasdaq Capital Market if it fails to regain compliance. Potential delisting could negatively affect the liquidity and market price of Propanc's common stock, reduce investor interest, hinder the company's ability to raise capital, and impair its capacity to offer equity incentives to employees. Propanc is monitoring its stock price and considering options to address the issue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-000834), on January 07, 2026, and is solely responsible for the information contained therein.